Robert Wooten, MD
Psychiatry · Pine Bluff, ARNPI 1922066232
Payments from drug & device makers
Across 712 payments — averaging $1327.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$333K
- Sumitomo Pharma America, Inc.$276K
- AbbVie$232K
- Neurocrine Biosciences, Inc.$63K
- Jazz Pharmaceuticals Inc.$36K
- Otsuka America Pharmaceutical, Inc.$810
- plus $3K from 20 others
What the payments were for
- Food & beverage$6,39598%
- Education$1412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 60 | $333,203 |
| Sumitomo Pharma America, Inc. | 101 | $276,138 |
| AbbVie(2 entities) | 212 | $232,328 |
| Neurocrine Biosciences, Inc. | 102 | $63,323 |
| Jazz Pharmaceuticals Inc. | 6 | $36,417 |
| Otsuka America Pharmaceutical, Inc. | 53 | $810 |
| Johnson & Johnson | 44 | $695 |
| Teva Pharmaceuticals USA, Inc. | 24 | $441 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $281 |
| Sunovion Pharmaceuticals Inc. | 26 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $188 |
| Alkermes, Inc. | 11 | $179 |
| Ironshore Pharmaceuticals Inc. | 9 | $158 |
| Vanda Pharmaceuticals Inc. | 10 | $147 |
| Eisai Inc. | 5 | $78 |
| Lundbeck LLC | 4 | $73 |
| Avanir Pharmaceuticals, Inc. | 4 | $62 |
| Shire North American Group Inc | 4 | $59 |
| Sun Pharmaceutical Industries Inc. | 3 | $59 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| Neuronetics, Inc. | 2 | $31 |
| Tris Pharma Inc | 1 | $21 |
| Livanova USA, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $14 |
| Corium, LLC | 1 | $12 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$945,022 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 21 | $200 |
| Gabapentin | 15 | $133 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Pine Bluff
- Abeer WashingtonPine Bluff$6K
- Stephen BroughtonPine Bluff$2K
- Leslie SmithLittle Rock$7.9M
- Gintaras AukstuolisLittle Rock$6.6M
- Robert BillingsleyFayetteville$5.9M
- Paul WylieLittle Rock$3.4M
- Prasad PadalaNorth Little Rock$868K
- Tad TillemansLittle Rock$656K
- Steven KoryElm Springs$628K
- Renea HendersonLittle Rock$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.